Bolt Biotherapeutics Inc’s filing revealed that its Senior VP, Finance and PAO Nemec Sarah acquired Company’s shares for reported $1241.0 on Dec 16 ’24. In the deal valued at $0.50 per share,2,500 shares were bought. As a result of this transaction, Nemec Sarah now holds 16,633 shares worth roughly $0.11 million.
Then, Quinn William P. bought 2,500 shares, generating $1,241 in total proceeds. Upon buying the shares at $0.50, the President, CEO and CFO now owns 41,272 shares.
Morgan Stanley downgraded its Bolt Biotherapeutics Inc [BOLT] rating to an Equal-weight from a an Overweight in a research note published recently. A number of analysts have revised their coverage, including SVB Leerink’s analysts, who began to cover the stock in early March with a ‘”an Outperform”‘ rating. Stifel began covering BOLT with “Buy” recommendation on March 02, 2021. Morgan Stanley started covering the stock on March 02, 2021. It rated BOLT as “an Overweight”.
Price Performance Review of BOLT
On Friday, Bolt Biotherapeutics Inc [NASDAQ:BOLT] saw its stock jump 0.62% to $6.50. Over the last five days, the stock has gained 6.38%. Bolt Biotherapeutics Inc shares have fallen nearly -39.26% since the year began. Nevertheless, the stocks have fallen -56.84% over the past one year. While a 52-week high of $15.60 was reached on 01/07/25, a 52-week low of $5.20 was recorded on 06/06/25. SMA at 50 days reached $6.8906, while 200 days put it at $10.1971.
Levels Of Support And Resistance For BOLT Stock
The 24-hour chart illustrates a support level at 5.6067, which if violated will result in even more drops to 4.7533. On the upside, there is a resistance level at 6.9067. A further resistance level may holdings at 7.3533. The Relative Strength Index (RSI) on the 14-day chart is 48.76, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0870, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 75.03%. Stochastics %K at 21.82% indicates the stock is a holding.
How much short interest is there in Bolt Biotherapeutics Inc?
A steep rise in short interest was recorded in Bolt Biotherapeutics Inc stocks on 2025-05-15, dropping by 2815.0 shares to a total of 12826.0 shares. Yahoo Finance data shows the prior-month short interest on 2025-04-15 was 15641.0 shares. There was a decline of -21.95%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 02, 2021 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $42 price target.
